Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microplasmin in Acute Intracranial Vertebrobasilar Artery Occlusion
NCT00123266Phase 2Terminated
- Sponsor
- Oxurion
- Start
- Dec 2006
- Primary completion
- Jul 2007
- Modality
- Therapeutic Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ocriplasmin in vertebrobasilar artery occlusion (VBAO), sponsored by Oxurion. Primary endpoint: Recanalization rate at Day 90. Started Dec 2006; status: terminated.
02
Drugs
ocriplasmin
03
Conditions
vertebrobasilar artery occlusion (VBAO)
Beyond the preview
Go deeper on NCT00123266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123266.